Already shipping, already regulated, already in clinical use across seven countries. The next phase compiles the proprietary backbone and ships the wedge product across UK and GCC.
The next major release of the live scribe — thirteen specialty consoles, vision-enabled, multilingual, expanded EHR push, and the structured-data ingest that feeds the proprietary backbone at production volume.
Each stage funds the next. We're not asking investors to underwrite year three — we're asking them to underwrite the proof points that unlock it.
ClinixSummary & ClinixQM live and MHRA Class I in hand. INTRCO and Education shipped as public demos. Seven countries.
Multi-specialty, vision-enabled, multilingual. Structured-data feed for the proprietary backbone.
Commercial alpha of the clinician-facing decision-support layer. UK + GCC pilots.
Sovereign inference, broader EHR integration and additional product surfaces opening sequentially.
Nov 2024 → August 2026. From idea to two live products, published preprints and two shipped demos — entirely organic.
The idea takes shape — a medical-native intelligence ecosystem rather than another single-purpose tool.
First developer onboarded. MVP build starts focused on real-time clinical documentation.
MVP launched on iOS & Android. Zero marketing spend — users find it organically.
The quality management platform goes live at clinixqm.gacrux.ai. Two products in market, validated product-market fit.
The next major release — thirteen specialty consoles, vision-enabled, multilingual, EHR push, and the structured-data ingest that feeds the proprietary backbone.
Two preprints posted on Research Square (Springer Nature) with registered DOIs: a pre-registered validation of within-population dose individualisation, and an independently checked test of cross-source synthesis over the compiled knowledge base. Read them on gatmedi.org.
Individualised treatment computation ships as a public demo at intrco.gacrux.ai — the medicine and the dose for this patient, not the guideline. The clinician-facing decision-support layer the roadmap set for H2 2026.
Medical revision that shows its working, at edu.gacrux.ai. The fourth surface off the same backbone.
Bootstrapped to $40M scenarios, monthly projections through 2028, use of funds, valuation framework and EHR-path detail — all available to verified investors on request.